Canton Strategic Holdings Inc
CNTNHealthcare|Biotechnology|US
$2.06
+0.13 (+6.74%)
DCF Value
$0.50
Cash / Share
$0.17
Financials
Financial Snapshot
Market Cap
$164.1M
Enterprise Value
$126.9M
Revenue (TTM)
$1.5M
Net Income (TTM)
-$98.1M
Cash & Investments
$37.2M
Net Cash
$37.2M
Free Cash Flow (TTM)
-$22.2M
Operating CF (TTM)
-$22.2M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$37.2M
Quarterly Burn
$5.5M
Monthly Burn
$1.8M
Est. Runway
~6.7 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $38.3K | $191.9K | $4.4K | $6.5M | $10.9M | $3.6M | $17.0M | $37.2M | |
| Operating Cash Flow | -$706.1K | -$1.1M | -$1.1M | -$6.6M | -$7.3M | -$10.9M | -$16.1M | -$22.2M | |
| Free Cash Flow | -$706.1K | -$1.1M | -$1.1M | -$6.6M | -$7.3M | -$10.9M | -$93.7M | -$22.2M | |
| Capital Expenditure | $3.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$77.6M | -$4.00 | |
| Financing Cash Flow | $708.4K | $1.2M | $898.7K | $13.1M | $11.7M | $3.5M | $107.2M | $195.9M |
R&D Spending
R&D (TTM)
$2.2M
R&D Intensity
147.2%
R&D Growth vs Prior
-28.4%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.5M | |
| R&D Expense | $368.7K | $847.3K | $1.8M | $2.3M | $3.6M | $6.4M | $3.1M | $2.2M | |
| R&D % of Revenue | — | — | — | — | — | — | — | 147.2% | |
| SG&A | $625.8K | $671.9K | $1.4M | $4.6M | $5.9M | $6.0M | $17.0M | $53.1M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.5M | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.5M | |
| R&D | $368.7K | $847.3K | $1.8M | $2.3M | $3.6M | $6.4M | $3.1M | $2.2M | |
| SG&A | $625.8K | $671.9K | $1.4M | $4.6M | $5.9M | $6.0M | $17.0M | $53.1M | |
| Operating Income | -$994.5K | -$1.5M | -$3.2M | -$6.9M | -$9.5M | -$12.4M | -$20.1M | -$53.8M | |
| Interest Expense | $75.1K | $246.5K | $831.3K | $1.6M | $16.5K | $13.7K | $28.3K | $13.7K | |
| Pretax Income | -$1.5M | -$2.4M | -$2.2M | -$8.5M | -$9.3M | -$12.2M | -$42.1M | -$113.9M | |
| Net Income | -$1.5M | -$2.4M | -$2.2M | -$8.5M | -$9.3M | -$12.2M | -$35.9M | -$98.1M | |
| EPS (Diluted) | -55.56 | -88.05 | -72.81 | -280.77 | -107.08 | -9.41 | -1.12 | -1.57 | |
| EBITDA | -$1.5M | -$2.2M | -$1.4M | -$5.3M | $152.6K | -$12.2M | -$20.1M | -$74.1M | |
| Shares Out. (M) | 0.03 | 0.03 | 0.03 | 0.03 | 0.09 | 1.30 | 32.05 | 216.86 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $38.3K | $191.9K | $4.4K | $6.5M | $10.9M | $3.6M | $17.0M | $37.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $40.9K | $294.8K | $621.7K | $6.7M | $10.9M | $3.7M | $17.4M | $41.2M | |
| Total Assets | $40.9K | $294.8K | $621.7K | $6.7M | $10.9M | $3.7M | $519.1M | $564.6M | |
| Total Current Liabilities | $1.1M | $2.7M | $4.5M | $1.1M | $1.8M | $2.4M | $3.3M | $2.6M | |
| Long-Term Debt | $532.8K | $1.3M | $772.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.7M | $4.0M | $5.3M | $1.1M | $1.8M | $2.4M | $121.2M | $109.7M | |
| Stockholders' Equity | -$1.6M | -$3.7M | -$4.7M | $5.5M | $9.1M | $1.3M | $397.9M | $454.9M | |
| Retained Earnings | -$2.1M | -$4.7M | -$6.9M | -$15.4M | -$24.7M | -$36.9M | -$72.8M | -$139.4M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$706.1K | -$1.1M | -$1.1M | -$6.6M | -$7.3M | -$10.9M | -$16.1M | -$22.2M | |
| Capital Expenditure | $3.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$77.6M | -$4.00 | |
| Free Cash Flow | -$706.1K | -$1.1M | -$1.1M | -$6.6M | -$7.3M | -$10.9M | -$93.7M | -$22.2M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$77.6M | -$138.2M | |
| Financing Cash Flow | $708.4K | $1.2M | $898.7K | $13.1M | $11.7M | $3.5M | $107.2M | $195.9M | |
| Issuance of Stock | $127.5K | $0.00 | $0.00 | $13.6M | $12.2M | $4.2M | $117.4M | $200.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | -$70.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $580.9K | $1.2M | $1.1M | -$14.6K | $0.00 | $0.00 | -$221.9K | -$191.5K | |
| Stock Based Comp. | $92.0K | $234.6K | $1.2M | $800.7K | $831.9K | $710.3K | $2.9M | $32.9M | |
| Net Change in Cash | $38.3K | $153.6K | -$187.5K | $6.5M | $4.4M | -$7.4M | $13.5M | $35.6M |
Dilution Tracker
Shares outstanding grew 116638.2% over 5 years — significant dilution
Shares Outstanding
80M
5-Year Share Growth
+116638.2%
Stock Issuance (TTM)
$200.8M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.03 | 0.03 | 0.03 | 0.03 | 0.09 | 1.30 | 32.05 | 216.86 | |
| Change vs Prior % | — | 0.0% | 10.4% | -0.4% | 188.4% | 1389.5% | 2372.4% | 576.7% | |
| Stock Issuance | $127.5K | $0.00 | $0.00 | $13.6M | $12.2M | $4.2M | $117.4M | $200.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | -$70.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $92.0K | $234.6K | $1.2M | $800.7K | $831.9K | $710.3K | $2.9M | $32.9M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | — | — | 100.0% | |
| Operating Margin % | — | — | — | — | — | — | — | -3595.2% | |
| Net Margin % | — | — | — | — | — | — | — | -6559.3% | |
| EBITDA Margin % | — | — | — | — | — | — | — | -4952.2% | |
| FCF Margin % | — | — | — | — | — | — | — | -1482.1% | |
| ROE % | 94.0% | 65.0% | 47.1% | -152.8% | -102.1% | -932.8% | -9.0% | -29.5% | |
| ROA % | -3731.5% | -820.0% | -355.0% | -126.7% | -85.1% | -327.7% | -6.9% | -17.4% | |
| ROIC % | 151.0% | 81.4% | 127.3% | -124.1% | -103.5% | -950.9% | -3.3% | -8.1% | |
| R&D / Revenue % | — | — | — | — | — | — | — | 147.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -52.7% | -111.2% | -114.5% | -37.4% | -31.5% | -61.7% | |
| Net Income | 0.0% | -58.5% | 8.7% | -284.0% | -10.0% | -30.9% | -194.5% | |
| EPS (Diluted) | 0.0% | -58.5% | 17.3% | -285.6% | 61.9% | 91.2% | 88.1% | |
| Operating Cash Flow | 0.0% | -52.7% | -0.7% | -503.7% | -11.3% | -49.3% | -47.9% | |
| Free Cash Flow | 0.0% | -52.7% | -0.7% | -503.7% | -11.3% | -49.3% | -759.5% | |
| R&D Expense | 0.0% | 129.8% | 117.5% | 23.6% | 56.2% | 79.6% | -51.9% | |
| SG&A Expense | 0.0% | 7.4% | 103.2% | 237.2% | 28.1% | 2.5% | 181.9% | |
| Total Assets | 0.0% | 621.1% | 110.9% | 975.9% | 63.7% | -66.0% | 13849.5% | |
| Book Value / Share | 0.0% | -129.2% | -14.2% | 218.8% | -42.9% | -99.0% | 1130.8% | |
| Debt | 0.0% | 92.1% | 17.0% | -100.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 10.4% | -0.4% | 188.4% | 1389.5% | 2372.4% |
Valuation
P/E (TTM)At Loss
P/S109.73
P/B0.98
10Y Low / Med / High0.07 / 0.80 / 2.01
EV/EBITDAAt Loss
EV/Revenue84.84
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.50
Cash / Share
$0.17
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -23.49 | -14.82 | -17.92 | -0.52 | -0.07 | -0.22 | -2.71 | -1.31 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 109.73 | |
| P/B Ratio | -22.09 | -9.64 | -8.44 | 0.80 | 0.07 | 2.01 | 0.24 | 0.98 | |
| EV/EBITDA | -25.34 | -17.27 | -30.33 | 0.40 | -67.29 | 0.08 | -3.99 | -1.71 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 84.84 |
Analyst Estimates & Quality
Altman Z-Score
0.12
Distress
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$24.0M | -$28.8M | -$33.7M |
| EPS | $-0.75 | $-0.90 | $-1.05 |
| # Analysts (EPS) | 1 | 1 | 1 |